Economy/Home · Economy

[Breaking] SK Biopharmaceuticals Files for Additional US FDA Approval of Xenobamate (XCOPRI) for Primary Generalized Tonic-Clonic Seizures in Patients Aged 12 and Older

SK Biopharmaceuticals announced on the 4th that it has filed for additional approval from the U.S. Food and Drug Administration (FDA) for cenobamate (U.S. brand name XCOPRI), an epilepsy treatment, as a therapy for primary generalized tonic-clonic (PGTC) seizures. The application covers patients ag

Oseong Kwon
Staff Reporter
5 min read
[Breaking] SK Biopharmaceuticals Files for Additional US FDA Approval of Xenobamate (XCOPRI) for Primary Generalized Tonic-Clonic Seizures in Patients Aged 12 and Older
CBC News

SK Biopharmaceuticals announced on the 4th that it has filed for additional approval from the U.S. Food and Drug Administration (FDA) for cenobamate (U.S. brand name XCOPRI), an epilepsy treatment, as a therapy for primary generalized tonic-clonic (PGTC) seizures.

The application covers patients aged 12 and older with primary generalized tonic-clonic seizures, and was filed on the 3rd, U.S. local time. Cenobamate is currently approved and marketed in the United States, Europe, and several other countries as a treatment for partial-onset seizures in adults. The latest filing seeks to expand its indications.

◆ Median 71.9% Reduction in Seizure Frequency in Clinical Trial

SK Biopharmaceuticals evaluated the efficacy and safety of cenobamate as adjunctive therapy through a multicenter clinical trial in which 169 patients with primary generalized tonic-clonic seizures were randomly assigned. The trial was conducted in a randomized, double-blind, placebo-controlled manner.

In the efficacy assessment, during the double-blind treatment period, the median percent change in seizure frequency measured at 28-day intervals from baseline was a 71.9% reduction in the cenobamate group. The placebo group showed a reduction of 39.6%, and the difference between the two groups was statistically significant (p=0.003).

◆ Safety Evaluation… No Serious Treatment-Related Adverse Events

In the safety evaluation, the incidence of adverse events was 60.0% in the cenobamate group and 53.0% in the placebo group. Most reported adverse events were mild to moderate. The incidence of serious adverse events was 5.9% and 1.2%, respectively, and no serious adverse events related to treatment occurred.

SK Biopharmaceuticals explained that primary generalized tonic-clonic seizures are a seizure type accompanied by risks of seizure-related injury and sudden unexpected death in epilepsy, while approved treatments remain limited. The company expects that cenobamate will provide patients with more treatment options and contribute to improving the quality of life of epilepsy patients.

However, the company stated that this regulatory submission does not guarantee final approval by the FDA. It added that the review process may produce results that fall short of expectations, and that it may accordingly modify or abandon its commercialization plans.

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.